Combined Phase 3 Double-blind Randomized Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn s Disease
Brief description of study
The purpose of this study is to see if filgotinib is effective and safe in treating people with moderate to severe Crohn’s disease. The study drug, filgotinib, is considered investigational in this study. Investigational means that the drug has not been approved by the Food and Drug Administration (FDA). Filgotinib is a selective JAK1 inhibitor. JAK1 is a protein inside certain cells(including immune cells) that may stimulate their activity. When immune cells are overactive, they can cause abdominal pain and diarrhea in Crohn’s disease patients. JAK1 inhibitors are believed to slow down the activity of the immune cells.
Clinical Study Identifier: s17-00389
ClinicalTrials.gov Identifier: NCT02914561
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
